0001725160-22-000032.txt : 20220214 0001725160-22-000032.hdr.sgml : 20220214 20220214210919 ACCESSION NUMBER: 0001725160-22-000032 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220210 FILED AS OF DATE: 20220214 DATE AS OF CHANGE: 20220214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gallagher Cam CENTRAL INDEX KEY: 0001557832 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 22636689 MAIL ADDRESS: STREET 1: 6042 CORNERSTONE CT. WEST STREET 2: SUITE B CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823607803 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1359 BROADWAY, SUITE 1710 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 1359 BROADWAY, SUITE 1710 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wf-form4_164489091255122.xml FORM 4 X0306 4 2022-02-10 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001557832 Gallagher Cam C/O ZENTALIS PHARMACEUTICALS, INC. 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 1 0 0 0 Common Stock 2022-02-10 4 A 0 8203 0 A 395406 D Common Stock 2022-02-10 4 A 0 7595 0 A 403001 D Common Stock 2022-02-14 4 S 0 2079 50.1642 D 400922 D Common Stock 2022-02-14 4 S 0 259 50.7472 D 400663 D Common Stock 2022-02-14 4 S 0 4850 50.1732 D 395813 D Stock Option (Right to Buy) 52.61 2022-02-10 4 A 0 19245 0 A 2032-02-09 Common Stock 19245.0 19245 D Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in full on the first anniversary of the grant date. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 17, 2021. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.77 to $50.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. By: /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher 2022-02-14